Skip to main content
SpringerLink
Log in

Colon Cancer and Other Gastrointestinal Malignancies

  • Chapter
Geriatric Medicine

  • 568 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Greenlee R, Hill-Harmon M, Murray T, Thum M. Cancer Statistics, 2001. CA Cancer J Clin. 2001;51:15–36.

    PubMed  CAS  Google Scholar 

  2. Yancik R, Ries L. Cancer in older persons. Cancer. 1994; 74:1995–2003.

    PubMed  CAS  Google Scholar 

  3. Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1973–1997. Bethesda, MD: National Cancer Institute; 2000.

    Google Scholar 

  4. Vercelli M, Capocaccia R, Quaglia A, Casella C, Puppo A, Coebergh J. Relative survival in elderly European cancer patients: evidence for health care inequalities. Crit Rev Oncol Hematol. 2000;35:161–179.

    PubMed  CAS  Google Scholar 

  5. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224–237.

    Article  PubMed  CAS  Google Scholar 

  6. Farniok K, Levitt S. The role of radiation therapy in the treatment of colorectal cancer. Implications for the older patient. Cancer. 1994;74:2154–2159.

    PubMed  CAS  Google Scholar 

  7. Giovanazzi-Bannon S, Rademaker A, Lai G, Benson A. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1994;12:2447–2452.

    PubMed  CAS  Google Scholar 

  8. Cascinu S, DelFerro E, Catalano G. Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol. 1996; 19:371–374.

    Article  PubMed  CAS  Google Scholar 

  9. Stein B, Petrelli N, Douglass H, Driscoll D, Arcangeli G, Meropol N. Age and sex are independant predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995;75:11–17.

    PubMed  CAS  Google Scholar 

  10. Pisani P, Parkin D, Bray F, Ferlay J. Estimates of the world-wide mortality from 25 cancers in 1990 [erratum: Int J Cancer 1999;83:870–873]. Int J Cancer. 1999;83:18–29.

    Article  PubMed  CAS  Google Scholar 

  11. Jessup J, McGinnis L, Steele G, Menck H, Winchester D. The National Cancer Data Base. Report on colon cancer. Cancer. 1996;78:918–926.

    Article  PubMed  CAS  Google Scholar 

  12. deRijke J, Schouten L, Hillen H, et al. Cancer in the very elderly Dutch population. Cancer. 2000;89:1121–1133.

    Article  PubMed  Google Scholar 

  13. Coburn M, Pricolo V, Soderberg C. Factors affecting prognosis and management of carcinoma of the colon and rectum in patients more than eighty years of age. J Am Coll Surg. 1994;179:65–69.

    PubMed  CAS  Google Scholar 

  14. Zhang B, Fattah A, Nakama H. Characteristics and survival rate of elderly patients with colorectal cancer detected by immunochemical occult blood screening. Hepatogastroenterology. 2000;47:414–418.

    PubMed  CAS  Google Scholar 

  15. Mulcahy H, Patchett S, Daly L, O’Donoghue D. Prognosis of elderly patients with large bowel cancer. Br J Surg. 1994;81:736–738.

    PubMed  CAS  Google Scholar 

  16. Damhuis R, Wereldsma J, Wiggers T. The influence of age on resection rates and postoperative mortality in 6,457 patients with colorectal cancer. Int J Colorectal Dis. 1996; 11:45–48.

    PubMed  CAS  Google Scholar 

  17. Adloff M, Ollier J, Schloegel M, Arnaud J, Serrat M. Colorectal cancer in patients over the age of 80 years. Ann Chir. 1993;47:492–496.

    PubMed  CAS  Google Scholar 

  18. Yancik R, Wesley M, Ries L, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients. Cancer. 1998;82:2123–2134.

    Article  PubMed  CAS  Google Scholar 

  19. Winawer S, Fletcher R, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997;112:594–642.

    Article  PubMed  CAS  Google Scholar 

  20. Fuchs C, Giovannucci E, Colditz G, Hunter D, Speizer F, Willett W. A propective study of family history and the risk of colorectal cancer. N Engl J Med. 1994;331:1669–1674.

    Article  PubMed  CAS  Google Scholar 

  21. Winawer S, Zauber A, Gerdes H, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. N Engl J Med. 1996;334:82–87.

    Article  PubMed  CAS  Google Scholar 

  22. Rustgi A. Hereditary gastrointestinal polyposis and nonpolyposis syndromes. N Engl J Med. 1994;331:1694–1702.

    Article  PubMed  CAS  Google Scholar 

  23. Burt R. Hereditary aspects of the polyposis syndromes. Hematol Oncol Annu. 1994;2:163–170.

    Google Scholar 

  24. Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA. 1997;277: 915–919.

    Article  PubMed  CAS  Google Scholar 

  25. Tomeo C, Colditz G, Willett W, et al. Harvard Report on Cancer Prevention. Volume 3: Prevention of colon cancer in the United States. Cancer Causes Control. 1999;10: 167–180.

    Article  PubMed  CAS  Google Scholar 

  26. Baron J, Greenberg E, Haile R, Mandel J, Sandler R, Mott L. Coffee and tea and the risk of recurrent colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 1997;6: 7–10.

    PubMed  CAS  Google Scholar 

  27. Fuchs C, Giovannucci E, Colditz G, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med. 1999;340:169–176.

    Article  PubMed  CAS  Google Scholar 

  28. Kinzler K, Vogelstein B. Colorectal tumors. In: Vogelstein B, Kinzler K, eds. The Genetic Basis of Human Cancer. New York: McGraw-Hill; 1998:565–587.

    Google Scholar 

  29. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med. 1998;339:1277–1284.

    Article  PubMed  CAS  Google Scholar 

  30. Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767.

    Article  PubMed  CAS  Google Scholar 

  31. Williams A, Balasooriya B, Day D. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut. 1982; 23:835–842.

    PubMed  CAS  Google Scholar 

  32. Yamamoto Y, Yin M, Lin K, Gaynor R. Sulindac inhibits activation of the NF-kappa B pathway. J Biol Chem. 1999; 274:27307–27314.

    Article  PubMed  CAS  Google Scholar 

  33. He T, Chan T, Vogelstein B, Kinzler K. PPARdelta is an APC-regulated target or nonsteroidal anti-inflammatory drug. Cell. 1999;99:335–345.

    Article  PubMed  CAS  Google Scholar 

  34. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois R. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–716.

    Article  PubMed  CAS  Google Scholar 

  35. Eberhart C, Coffey R, Radhika A, Giardiello F, Ferrenbach S, DuBois R. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–1188.

    PubMed  CAS  Google Scholar 

  36. Oshima M, Dinchuk J, Kargman S, et al. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87: 803–809.

    Article  PubMed  CAS  Google Scholar 

  37. Giardiello F, Hamilton S, Krush A, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313–1316.

    Article  PubMed  CAS  Google Scholar 

  38. Steinbach G, Lynch P, Phillips R, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–1952.

    Article  PubMed  CAS  Google Scholar 

  39. Thun M, Namboodiri M, Heath C. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med.1991; 325:1593–1596.

    Article  PubMed  CAS  Google Scholar 

  40. Giovannucci E, Rimm E, Stampfer M, Colditz G, Asherio A, Willett W. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241–246.

    PubMed  CAS  Google Scholar 

  41. Giovannucci E, Egan K, Hunter D, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995; 333:609–614.

    Article  PubMed  CAS  Google Scholar 

  42. Smalley W, Ray W, Daugherty J, Griffin M. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med. 1999;159:161–166.

    Article  PubMed  CAS  Google Scholar 

  43. Giovannucci E, Stampfer M, Colditz G, Rimm E, Willett W. Relationship of diet to risk of colorectal adenoma in men. J Natl Cancer Inst. 1992;84:91–98.

    PubMed  CAS  Google Scholar 

  44. Thun M, Calle E, Namboodiri M, et al. Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst. 1992;84:1491–1500.

    PubMed  CAS  Google Scholar 

  45. Baron J, Sandler R, Haile R, Mandel J, Mott L, Greenberg E. Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. J Natl Cancer Inst. 1998; 90:57–62.

    Article  PubMed  CAS  Google Scholar 

  46. Ferraroni M, LaVecchia C, D’Avanzo B, Negri E, Franceschi S, Decarli A. Selected micronutrient uptake and the risk of colorectal cancer. Br J Cancer. 1994;70: 1150–1155.

    PubMed  CAS  Google Scholar 

  47. Giovannucci E, Stampfer M, Colditz G, et al. Multivitamin use, folate, and colon cancer in women in the Nurses’ Health Study. Ann Intern Med. 1998;129:517–524.

    PubMed  CAS  Google Scholar 

  48. Nagengast F, Grubben M, vanMunster I. Role of bile acids in colorectal carcinogenesis. Eur J Cancer. 1995;31A:1067–1070.

    Article  PubMed  CAS  Google Scholar 

  49. Hyman J, Baron J, Dain B, et al. Dietary and supplemental calcium and the recurrence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 1998;7:291–295.

    PubMed  CAS  Google Scholar 

  50. Baron J, Beach M, Mandel J, et al. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med. 1999;340:101–107.

    Article  PubMed  CAS  Google Scholar 

  51. McMichael A, Potter J. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst. 1980;65:1201–1207.

    PubMed  CAS  Google Scholar 

  52. Grodstein F, Newcomb P, Stampfer M. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999;106:574–582.

    Article  PubMed  CAS  Google Scholar 

  53. Calle E, Miracle-McMahill H, Thun M, Heath C. Estrogen replacement therapy and the risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995;87:517–523.

    PubMed  CAS  Google Scholar 

  54. Grodstein F, Martinez E, Platz E, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med. 1998;128:705–712.

    PubMed  CAS  Google Scholar 

  55. Greenberg E, Baron J, Tosteson T, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med. 1994;331:141–147.

    Article  PubMed  CAS  Google Scholar 

  56. Hennekens C, Buring J, Manson J, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145–1149.

    Article  PubMed  CAS  Google Scholar 

  57. Albanes D, Malila N, Taylor P, et al. Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer: results from a controlled trial. Cancer Causes Control. 2000;11:197–205.

    Article  PubMed  CAS  Google Scholar 

  58. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. N Engl J Med. 2000;342:1149–1155.

    Article  PubMed  CAS  Google Scholar 

  59. Alberts D, Martinez M, Roe D, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. N Engl J Med. 2000;342:1156–1162.

    Article  PubMed  CAS  Google Scholar 

  60. Muller A, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med. 1995;123:904–910.

    PubMed  CAS  Google Scholar 

  61. Winawer S, Zauber A, Ho M, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med. 1993;329:1977–1981.

    Article  PubMed  CAS  Google Scholar 

  62. Curless R, French J, Williams G, James O. Comparison of gastrointestinal symptoms in colorectal carcinoma patients and community controls with respect to age. Gut. 1994;35:1267–1270.

    PubMed  CAS  Google Scholar 

  63. Wanebo H, Rao B, Pinsky C, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med. 1978;299:448–451.

    Article  PubMed  CAS  Google Scholar 

  64. Moertel C, O’Fallon J, Go V, O’Connell M, Thynne G. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer. 1986;58:603–610.

    PubMed  CAS  Google Scholar 

  65. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol. 1996;14:2843–2877.

    Google Scholar 

  66. Moertel C, Fleming T, Macdonald J, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321–326.

    PubMed  CAS  Google Scholar 

  67. Schrag D, Cramer L, Bach P, Cohen A, Warren J, Begg C. Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA. 2000;284:3028–3035.

    Article  PubMed  CAS  Google Scholar 

  68. Lewis A, Khoury G. Resection for colorectal cancer in the very old: are the risks too high? Br Med J (Clin Res Ed.) 1988;296:459–461.

    CAS  Google Scholar 

  69. Whittle J, Steinberg E, Anderson G, Herbert R. Results of colectomy in elderly patients with colon cancer, based on Medicare claims data. Am J Surg. 1992;163:572–576.

    Article  PubMed  CAS  Google Scholar 

  70. Whittle J, Steinberg E, Anderson G, Herbert R. Results of colectomy in elderly patients with colon cancer, based on Medicare claims data. Am J Surg. 1992;163:572–576.

    Article  PubMed  CAS  Google Scholar 

  71. McDermott F, Hughes E, Pihl E, Johnson W, Price A. Local recurrence after potentially curative resection for rectal cancer in a series of 1008 patients. Br J Surg. 1985;72: 34–37.

    PubMed  CAS  Google Scholar 

  72. Wilson S, Beahrs O. The curative treatment of carcinoma of the sigmoid, rectosigmoid, and rectum. Ann Surg. 1976; 183:556–565.

    PubMed  CAS  Google Scholar 

  73. Graham R, Garnsey L, Jessup J. Local excision of rectal carcinoma. Am J Surg. 1990;160:306–312.

    PubMed  CAS  Google Scholar 

  74. Steele G, Herndon J, Bleday R, et al. Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol. 1999;6:413–415.

    Article  Google Scholar 

  75. Bleday R, Breen E, Jessup J, Burgess A, Sentovich S, Steele G. Prospective evaluation of local excision for small rectal cancers. Dis Colon Rectum. 1997;40:388–392.

    Article  PubMed  CAS  Google Scholar 

  76. Haller D, Catalano P, Macdonald J, Mayer R. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: four-year results of INT-0089. Proc Annu Meet Am Soc Clin Oncol. 1997;16:A940.

    Google Scholar 

  77. Moertel C, Fleming T, Macdonald J, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol. 1995;13: 2936–2943.

    PubMed  CAS  Google Scholar 

  78. Minsky B, Mies C, Rich T, Recht A. Lymphatic vessel invasion is an independant prognostic factor for survival in colorectal cancer. Int J Radiat Oncol Biol Phys. 1989;17:311–318.

    PubMed  CAS  Google Scholar 

  79. Chapuis P, Dent O, Fisher R, et al. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg. 1985;72:698–702.

    PubMed  CAS  Google Scholar 

  80. Evans R, Laskin J, Hakala M. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res. 1980;40:4113–4122.

    PubMed  CAS  Google Scholar 

  81. Santi D, McHenry C, Sommer H. Mechanism of interaction of thymidylate synthase with fluorodeoxyuridylate. Biochemistry. 1974;13:471–480.

    Article  PubMed  CAS  Google Scholar 

  82. Danenberg P, Danenberg K. Effect of 5,10-methylenete-trahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry. 1978;17:4018–4024.

    Article  PubMed  CAS  Google Scholar 

  83. Sundararajan V, Grann V, Neugut A. Population-based variation in the use of chemotherapy for colorectal cancer in the elderly. Proc Am Soc Clin Oncol. 1999;18:A1598.

    Google Scholar 

  84. Sargent D, Goldberg R, MacDonald J, et al. Adjuvant chemotherapy for colon cancer (cc) is beneficial without significantly increased toxicity in elderly patients (pts): results from a 3351-pt meta-analysis. Proc Am Soc Clin Oncol. 2000;19:A933.

    Google Scholar 

  85. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med. 1985;312:1465–1472.

    Article  Google Scholar 

  86. Tepper J, O’Connell M, Petroni G, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of Intergroup 0114. J Clin Oncol. 1997;15:2030–2039.

    PubMed  CAS  Google Scholar 

  87. O’Connell M, Martenson J, Wieand H, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331:502–507.

    Article  PubMed  CAS  Google Scholar 

  88. Minsky B, Cohen A, Kemeny N, et al. Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol. 1992;10:1218–1224.

    PubMed  CAS  Google Scholar 

  89. Swedish Rectal Cancer Trial. Local recurrence rate in a randomised multicentre trial of preoperative radiotherapy compared with operation alone in resectable rectal carcinoma. Eur J Surg. 1996;162:397–3402.

    Google Scholar 

  90. Farniok K, Levitt S. The role of radiation therapy in the treatment of colorectal cancer. Implications for the older patient. Cancer. 1994;74:2154–2159.

    PubMed  CAS  Google Scholar 

  91. Castells A, Bessa X, Daniels M, et al. Value of postoperative surveillance after radical surgery for colorectal cancer: results of a cohort study. Dis Colon Rectum. 1998;41:714–723.

    Article  PubMed  CAS  Google Scholar 

  92. Graham R, Wang S, Catalano P, Haller D. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg. 1998;228:59–63.

    Article  PubMed  CAS  Google Scholar 

  93. Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology. 1998;114:7–14.

    Article  PubMed  CAS  Google Scholar 

  94. Benson A, Desch C, Flynn P, et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol. 2000;18:3586–3588.

    PubMed  Google Scholar 

  95. Moertel C, Fleming T, Macdonald J, Haller D, Laurie J, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943–947.

    Article  PubMed  CAS  Google Scholar 

  96. Goldberg R, Fleming T, Tangen C, et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Ann Intern Med. 1998;129:27–35.

    PubMed  CAS  Google Scholar 

  97. Fong Y, Blumgart L. Hepatic colorectal metastasis: current status of surgical therapy. Oncology. 1998;12:1489–1498.

    PubMed  CAS  Google Scholar 

  98. Fong Y, Blumgart L, Fortner J, Brennan M. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg. 1995;222:426–434.

    PubMed  CAS  Google Scholar 

  99. McKenna R. Thoracoscopic lobectomy with mediastinal sampling in 80-year-old patients. Chest. 1994;106:1902–1904.

    PubMed  Google Scholar 

  100. Kemeny N, Huang Y, Cohen A, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039–2048.

    Article  PubMed  CAS  Google Scholar 

  101. Kemeny M, Adak S, Lipitz S, Gray B, MacDonald J, Benson A. Results of Intergroup [Eastern Cooperative Group (ECOG) and Southwest Oncology Group (SWOG)] prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUdR and continuous systemic infusion of 5FU after hepatic resection of colorectal liver metastases. Proc Am Soc Clin Oncol. 1999;18:A1012.

    Google Scholar 

  102. Scheithauer W, Rosen H, Kornek G, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J. 1993;306:752–755.

    CAS  Google Scholar 

  103. Unger J, Hutchins L, Crowley J, Coltman C, Albain K. Southwest Oncology Group (SWOG) accrual by sex, race, and age, compared to US population rates. Proc Am Soc Clin Oncol. 1998;17:A1596.

    Google Scholar 

  104. Trimble E, Carter C, Cain D, Freidlin B, Ungerleider R, Friedman M. Representation of older patients in cancer treatment trials. Cancer. 1994;74:2208–2214.

    PubMed  CAS  Google Scholar 

  105. Ross P, Popescu R, Cunningham D, Norman A, Parikh B. Adjuvant and palliative chemotherapy for colorectal cancer in patients aged 70 years or older. Proc Am Soc Clin Oncol. 1998;17:A1069.

    Google Scholar 

  106. Pitot H. US pivotal studies of irinotecan in colorectal carcinoma. Oncology. 1998;12:48–53.

    PubMed  CAS  Google Scholar 

  107. Cunningham D, Pyrhoenen S, James R, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413–1418.

    Article  PubMed  CAS  Google Scholar 

  108. Saltz L, Cox J, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905–914.

    Article  PubMed  CAS  Google Scholar 

  109. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301–308.

    Google Scholar 

  110. Hoff P. Capecitabine as first-line treatment for colorectal cancer (CRC): integrated results of 1207 patients (pts) from 2 randomized, phase III studies. On behalf of the Capecitabine CRC Study Group. Presented at the 25th European Society for Medical Oncology Congress, Hamburg, Germany, 2000.

    Google Scholar 

  111. Machover D, Diza-Rubio E, deGramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol. 1996;7:95–98.

    PubMed  CAS  Google Scholar 

  112. Rubin M, Shin D, Pasmantier M, et al. Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr), for patients (pts) with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens. Proc Am Soc Clin Oncol. 2000;19:A1860.

    Google Scholar 

  113. Fuchs C, Colditz G, Stampfer M, et al. Prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med. 1996;156:2255–2260.

    Article  PubMed  CAS  Google Scholar 

  114. Lowenfels A, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328:1433–1437.

    Article  PubMed  CAS  Google Scholar 

  115. Silverman D, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer. 1999;80:1830–1837.

    Article  PubMed  CAS  Google Scholar 

  116. Karlson B, Ekbom A, Josefsson S, McLaughlin J, Fraumeni J, Nyren O. The risk of pancreatic cancer following pancreatitis an association due to confounding? Gastroenterology. 1997;113:587–592.

    Article  PubMed  CAS  Google Scholar 

  117. Gullo L, Pezzilli R, Morselli-Labate A. Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group. N Engl J Med. 1994;331:81–84.

    Article  PubMed  CAS  Google Scholar 

  118. Goggins M, Canto M, Hruban R. Can we screen high-risk individuals to detect early pancreatic carcinoma? [editorial]. J Surg Oncol. 2000;74:243–248.

    Article  PubMed  CAS  Google Scholar 

  119. Safi F, Schlosser W, Falkenreck S, Beger H. Prognostic value of CA19-9 serum course in pancreatic cancer. Hepatogastroenterology. 1998;45:253–259.

    PubMed  CAS  Google Scholar 

  120. Nieman J, Holmes F. Accuracy of diagnosis of pancreatic cancer decreases with increasing age. J Am Geriatr Soc. 1989;37:97–100.

    PubMed  CAS  Google Scholar 

  121. Brandt K, Charboneau J, Stephens D, Welch T, Goellner J. CT-and US-guided biopsy of the pancreas. Radiology. 1993;187:15–16.

    Google Scholar 

  122. Cameron J. The current management of carcinoma of the head of the pancreas. Annu Rev Med. 1995;46:361–370.

    Article  PubMed  CAS  Google Scholar 

  123. Nitecki S, Sarr M, Colby T, vanHeerden J. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995;221:59–66.

    PubMed  CAS  Google Scholar 

  124. Spencer M, Sarr M, Nagorney D. Radical pancreatectomy for pancreatic cancer in the elderly. Is it safe and justified? Ann Surg. 1990;212:140–143.

    PubMed  CAS  Google Scholar 

  125. Sohn T, Yeo C, Cameron J, et al. Should pancreaticoduodenectomy be performed in octogenarians? J Gastrointest Surg. 1998;2:207–216.

    Article  PubMed  CAS  Google Scholar 

  126. Bottger T, Engelmann R, Junginger T. Is age a risk factor for major pancreatic surgery? An analysis of 300 resections. Hepatogastroenterology. 1999;46:2589–2598.

    PubMed  CAS  Google Scholar 

  127. al-Sharaf K, Andren-Sandberg A, Ihse I. Subtotal pancreatectomy for cancer can be safe in the elderly. Eur J Surg. 1999;165:230–235.

    Article  PubMed  CAS  Google Scholar 

  128. DiCarlo V, Balzano G, Zerbi A, Villa E. Pancreatic cancer resection in elderly patients. Br J Surg. 1998;85:607–610.

    Article  Google Scholar 

  129. Gastrointestinal Tumor Study Group. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.

    Google Scholar 

  130. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006–2010.

    Google Scholar 

  131. Klinkenbijl J, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg. 1999;230:776–782.

    Article  PubMed  CAS  Google Scholar 

  132. Neoptolemos J, Dunn J, Mofitt D, et al. ESPAC-1 interim results: a European, randomized study to assess the roles of adjuvant chemotherapy (5FU + folinic acid) and adjuvant chemoradiation (40 Gy + 5FU) in resectable pancreatic cancer. Br J Cancer. 2000;83:CT1.

    Google Scholar 

  133. Evans D, Abbruzzese J, Lee J, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas M.D. Anderson experience. Semin Surg Oncol. 1995;11:132–140.

    Google Scholar 

  134. Cienfuegos J, Manuel F. Analysis of intraoperative radiotherapy for pancreatic carcinoma. Eur J Surg Oncol. 2000;26:S13–S15.

    PubMed  Google Scholar 

  135. Lillemoe K, Cameron J, Kaufman H, Yeo C, Pitt H, Sauter P. Chemical splanchnicectomy in patients with unresectable pancreatic cancer a prospective randomized trial. Ann Surg. 1993;217:447–455.

    PubMed  CAS  Google Scholar 

  136. Haslam J, Cavanaugh P, Strapp S. Radiation therapy in the treatment of unresectable adenocarcinoma of the pancreas. Cancer. 1973;32:1341–1345.

    PubMed  CAS  Google Scholar 

  137. Moertel C, Childs D, Reitemeir R, Colby M, Holbrook M. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2:865–867.

    Article  PubMed  CAS  Google Scholar 

  138. Moertel C, Frytak S, Hahn R, et al. Therapy of locally unresectable pancreatic carcinoma a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil.. Cancer. 1981;48:1705–1710.

    PubMed  CAS  Google Scholar 

  139. Cullinan S, Moertel C, Fleming T, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Flurouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985;253:2061–2067.

    Article  PubMed  CAS  Google Scholar 

  140. Cullinan S, Moertel C, Wieand H, et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer. 1990;65 2207–2212.

    PubMed  CAS  Google Scholar 

  141. Mallinson C, Rake M, Cocking J, et al. Chemotherapy in pancreatic cancer results of a controlled, prospective, randomized, multicentre trial. Br Med J. 1980;281:1589–1591.

    Article  PubMed  CAS  Google Scholar 

  142. Palmer K, Kerr M, Knowles G, Cull A, Carter D, Leonard R. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg. 1994;81:882–885.

    PubMed  CAS  Google Scholar 

  143. Casper E, Green M, Kelsen D, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Investig New Druges. 1994;12:29–34.

    Article  CAS  Google Scholar 

  144. Carmichael J, Fink U, Russell R, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996;73:101–105.

    PubMed  CAS  Google Scholar 

  145. Burris H, Moore M, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer a randomized trial. J Clin Oncol. 1997;15:2403–2413.

    PubMed  CAS  Google Scholar 

  146. Rykowski J, Hilgier M. Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer influence on pain relief. Anesthesiology. 2000;92:347–354.

    Article  PubMed  CAS  Google Scholar 

  147. Marra V, Debernardi F, Frigerio A, Menna S, Musso L, DiVirgilio M. Neurolytic block of the celiac plexus and splanchnic nerves with computed tomography. The experience in 150 cases and an optimization of the technic. Radiol Med (Torino). 1999;98:183–188.

    CAS  Google Scholar 

  148. Devesa S, Blot W, Fraumeni J. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053.

    Article  PubMed  CAS  Google Scholar 

  149. Neugut A, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol. 1996;23:281–291.

    PubMed  CAS  Google Scholar 

  150. Palli D. Epidemiology of gastric cancer an evaluation of available evidence. J Gastroenterol. 2000;35:84–89.

    PubMed  Google Scholar 

  151. Stolet M, Meining A. Helicobacter pylori and gastric cancer. Oncologist. 1998;3:124–128.

    Google Scholar 

  152. Eslick G, Lim L, Byles J, Xia H, Talley N. Association of Helicobacter pylori infection with gastric carcinoma a meta-analysis. Am J Gastroenterol. 1999;94:2373–2379.

    Article  PubMed  CAS  Google Scholar 

  153. You W, Zhang L, Hail M, et al. Gastric dysplasia and gastric cancer Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst. 2000;92:1607–1612.

    Article  PubMed  CAS  Google Scholar 

  154. Karlson B, Ekbom A, Wacholder S, McLaughlin J, Hsing A. Cancer of the upper gastrointestinal tract among patients with pernicious anemia a case-cohort study. Scand J Gastroenterol. 2000;35:847–851.

    Article  PubMed  CAS  Google Scholar 

  155. Bajtai A, Hidvegi J. The role of gastric mucosal dysplasia in the development of gastric carcinoma. Pathol Oncol Res. 1998;4:297–300.

    Article  PubMed  CAS  Google Scholar 

  156. Hansson L, Nyren O, Hsing A, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med. 1996;335:242–249.

    Article  PubMed  CAS  Google Scholar 

  157. Lundegardh G, Adami H, Helmick C, Zack M, Meirik O. Stomach cancer after partial gastrectomy for benign ulcer disease. N Engl J Med. 1988;319:195–200.

    Article  PubMed  CAS  Google Scholar 

  158. Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997;6:639–642.

    PubMed  CAS  Google Scholar 

  159. Wanebo H, Kennedy B, Chmiel J, Steele G, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218 583–592.

    PubMed  CAS  Google Scholar 

  160. Siewert J, Bottcher K, Stein H, Roder J. Relevant prognostic factors in gastric cancer ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449–461.

    Article  PubMed  CAS  Google Scholar 

  161. Estes N, MacDonald J, Touijer K, Benedetti J, Jacobson J. Inadequate documentation and resection for gastric cancer in the United States a preliminary report. Am Surg. 1998;64:680–685.

    PubMed  CAS  Google Scholar 

  162. Bonenkamp J, Hermans J, Sasako M, vandeVelde C. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–914.

    Article  PubMed  CAS  Google Scholar 

  163. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522–1530.

    Article  PubMed  CAS  Google Scholar 

  164. Schwarz R, Karpeh M, Brennan M. Factors predicting hospitalization after operative treatment for gastric carcinoma in patients older than 70 years. J Am Coll Surg. 1997;184:9–15.

    PubMed  CAS  Google Scholar 

  165. Hermans J, Bonenkamp J, Boon M, et al. Adjuvant therapy after curative resection for gastric cancer meta-analysis of randomized trials. J Clin Oncol. 1993;11:1441–1447.

    PubMed  CAS  Google Scholar 

  166. Earle C, Maroun J. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients revisiting a meta-analysis of randomized trials. Eur J Cancer. 1999;37:1059–1064.

    Article  Google Scholar 

  167. Hallissey M, Dunn J, Ward L, Allum W. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer five-year follow-up. Lancet. 1994;343:1309–1312.

    Article  PubMed  CAS  Google Scholar 

  168. Childs D, Moertel C, Holbrook M, Reitemeier R, Colby M. Treatment of unresectable adenocarcinomas of the stomach with a combination of 5-fluorouracil and radiation. Am J Roentgenol Radium Ther Nucl Med. 1968;102 541–544.

    PubMed  Google Scholar 

  169. Macdonald J, Smalley S, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves survival in resected adenocarcinoma of the stomach and GE junction. Results of Intergroup Study INT-0116 (SWOG 9008). Proc Am Soc Clin Oncol. 2000;19:A1.

    Google Scholar 

  170. Macdonald JS, Smalley SR, Benedetti J. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730.

    Article  PubMed  CAS  Google Scholar 

  171. Smalley S, Benedetti J, Gunderson L, et al. Intergroup 0116 (SWOG 9008) phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma evaluation of efficacy and radiotherapy treatment planning. Int J Radiat Oncol Biol Phys. 2000;48:111–112.

    Article  Google Scholar 

  172. Ekbom G, Gleysteen J. Gastric malignancy resection for palliation. Surgery. 1980;88:476–481.

    PubMed  CAS  Google Scholar 

  173. Bozzetti F, Bonfanti G, Audisio R, et al. Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. Surg Gynecol Obstet. 1987;164 151–154.

    PubMed  CAS  Google Scholar 

  174. Boddie A, McMurtrey M, Giacco G, McBride C. Palliative total gastrectomy and esophagogastrectomy. A reevaluation. Cancer. 1983;51:1195–1200.

    PubMed  Google Scholar 

  175. Meijer S, DeBakker O, Hoitsma H. Palliative resection in gastric cancer. J Surg Oncol. 1983;23:77–80.

    PubMed  CAS  Google Scholar 

  176. Murad A, Santiago F, Petroianu A, Rocha P, Rodrigues M, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37–41.

    PubMed  CAS  Google Scholar 

  177. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587–591.

    PubMed  CAS  Google Scholar 

  178. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy puls best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163–168.

    Article  PubMed  CAS  Google Scholar 

  179. Kulke M. The treatment of advanced gastric cancer in search of the right combination. J Clin Oncol. 2000; 18:2645–2647.

    PubMed  CAS  Google Scholar 

  180. Levi J, Fox R, Tattersall M, Woods R, Thomson D, Gill G. Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future sutdues. J Clin Oncol. 1986;4:1348–1355.

    PubMed  CAS  Google Scholar 

  181. Cullinan S, Moertel C, Wieand H, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol. 1994;12:412–416.

    PubMed  CAS  Google Scholar 

  182. Ross P, Hill M, Norman A, Cunningham D. ECF in gastric cancer [letter]. J Clin Oncol. 2000;18:3874–3875.

    PubMed  CAS  Google Scholar 

  183. Webb A, Cunningham D, Scarffe J, et al. Randomized trial comparing epirubicin, cisplatin, fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261–267.

    PubMed  CAS  Google Scholar 

  184. Ajani J. Chemotherapy for gastric carcinoma: new and old options. Oncology. 1998;12:44–47.

    PubMed  CAS  Google Scholar 

  185. Gammon M, Schoenberg J, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1997; 89:1277–1284.

    Article  PubMed  CAS  Google Scholar 

  186. Blot W, McLaughlin J. The changing epidemiology of esophageal cancer. Semin Oncol. 1999;25:2–8.

    Google Scholar 

  187. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831.

    Article  PubMed  CAS  Google Scholar 

  188. Spechler S. Barrett’s esophagus. Semin Oncol. 1994;21: 431–437.

    PubMed  CAS  Google Scholar 

  189. Vaughan T, Farrow D, Hansten P, et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev. 1998;7:749–756.

    PubMed  CAS  Google Scholar 

  190. Lagergren J, Bergstrom R, Adami H, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med. 2000;133:165–175.

    PubMed  CAS  Google Scholar 

  191. Chow W, Blot W, Vaughan T, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90:150–155.

    Article  PubMed  CAS  Google Scholar 

  192. Naunheim K, Hanosh J, Zwischenberger J, et al. Esophagectomy in the septuagenarian. Ann Thorac Surg. 1993;56:880–883.

    Article  PubMed  CAS  Google Scholar 

  193. Ellis F, Williamson W, Heatley G. Cancer of the esophagus and cardia: does age influence treatment selection and surgical outocmes? J Am Coll Surg. 1998;187:345–351.

    Article  PubMed  Google Scholar 

  194. Enzinger P, Ilson D, Kelsen D. Chemotherapy in esophageal cancer. Semin Oncol. 1999;26:12–20.

    PubMed  CAS  Google Scholar 

  195. Reed C. Surgical management of esophageal carcinoma. Oncologist. 1999;4:95–105.

    PubMed  CAS  Google Scholar 

  196. Morales T, Sampliner R. Barrett’s esophagus: update on screening, surveillance, and treatment. Arch Intern Med. 1999;159:1411–1416.

    Article  PubMed  CAS  Google Scholar 

  197. Streitz J, Ellis F, Tilden R, Erickson R. Endoscopic surveillance of Barrett’s esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol. 1998;93:911–915.

    Article  PubMed  Google Scholar 

  198. Lerut T, Coosemans W, Raemdonck D, et al. Surgical treatment of Barrett’s carcinoma. Correlations between morphologic findings and prognosis. J Thorac Cardiovasc Surg. 1994;107:1059–1065.

    PubMed  CAS  Google Scholar 

  199. Streitz J, Andrews C, Ellis F. Endoscopic surveillance of Barrett’s esophagus. Does it help? J Thorac Cardiovasc Surg. 1993;105:383–387.

    PubMed  Google Scholar 

  200. Beck I, Champion M, Lemire S, et al. The Second Canadian Consensus Conference on the management of patients with gastroesophageal reflux disease. Can J Gastroenterol. 1997;11:7B–20B.

    PubMed  Google Scholar 

  201. Rusch V, Levine D, Haggitt R, Reid B. The management of high grade dysplasia and early cancer in Barrett’s esophagus. A multidisciplinary problem. Cancer. 1994;74: 1225–1229.

    PubMed  CAS  Google Scholar 

  202. Corti L, Skarlatos J, Boso C, et al. Outcome of patients receiving photodynamic therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2000;47:419–424.

    Article  PubMed  CAS  Google Scholar 

  203. Sharma P, Jaffe P, Bhattacharyya A, Sampliner R. Laser and multipolar electrocoagulation ablation of early Barrett’s adenocarcinoma: long-term follow-up. Gastroin-test Endosc. 1999;49:442–446.

    Article  CAS  Google Scholar 

  204. Flamen P, Lerut A, VanCutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophagela carcinoma. J Clin Oncol. 2000;18:3202–3210.

    PubMed  CAS  Google Scholar 

  205. Pommier R, Vetto J, Ferris B, Wilmarth T. Relationships between operative approaches and outcomes in esophageal cancer. Am J Surg. 1998;175:422–425.

    Article  PubMed  CAS  Google Scholar 

  206. Goldminc M, Maddern G, LePrise E, Meunier B, Campion J, Launois B. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg. 1993;80:367–370.

    PubMed  CAS  Google Scholar 

  207. Bosset J, Gignoux M, Triboulet J, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161–167.

    Article  PubMed  CAS  Google Scholar 

  208. Kelsen D, Ginsberg R, Pajak T, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339: 1979–1984.

    Article  PubMed  CAS  Google Scholar 

  209. Alexiou C, Beggs D, Salama F, Brackenbury E, Morgan W. Surgery for esophageal cancer in elderly patients: the view from Nottingham. J Thorac Cardiovasc Surg. 1998;116: 545–553.

    Article  PubMed  CAS  Google Scholar 

  210. Thomas P, Doddoli C, Neville P, et al. Esophageal cancer resection in the elderly. Eur J Cardiothorac Surg. 1996; 10:941–946.

    Article  PubMed  CAS  Google Scholar 

  211. Jougon J, Ballester M, Duffy J, et al. Esophagectomy for cancer in the patient aged 70 years and older. Ann Thorac Surg. 1997;63:1423–1427.

    Article  PubMed  CAS  Google Scholar 

  212. Dalrymple-Hay M, Evans K, Lea R. Surgery for oesophageal carcinoma in the elderly. Acta Chir Hung. 1999;38:27–29.

    PubMed  CAS  Google Scholar 

  213. Adam D, Craig S, Sang C, Cameron E, Walker W. Esophagectomy for carcinoma in the octogenarian. Ann Thorac Surg. 1996;61:190–194.

    Article  PubMed  CAS  Google Scholar 

  214. Earlam R, Cunha-Melo J. Oesophageal squamous cell carcinoma: II. A critical review of radiotherapy. Br J Surg. 1980;67:457–461.

    PubMed  CAS  Google Scholar 

  215. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–1598.

    Article  PubMed  CAS  Google Scholar 

  216. Al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an Intergroup study. J Clin Oncol. 1997;15:277–284.

    PubMed  CAS  Google Scholar 

  217. Smith T, Ryan L, Douglass H, et al. Combined chemoradiotherapy vs radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42:269–276.

    Article  PubMed  CAS  Google Scholar 

  218. Arnott S, Duncan W, Gignoux M, et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys. 1998;41:579–583.

    Article  PubMed  CAS  Google Scholar 

  219. Clark P. Medical Research Council (MRC) randomized phase III trial of surgery with or without preoperative chemotherapy in resectable cancer of the oesophagus. Br J Cancer. 2000;83:CT2.

    Google Scholar 

  220. Forastiere A, Orringer M, Perez-Tamayo C, Urba S, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993;11:1118–1123.

    PubMed  CAS  Google Scholar 

  221. Sauter E, Coia L, Keller S. Preoperative high-dose radiation and chemotherapy in adenocarcinoma of the esophagus and esophagogastric junction. Ann Surg Oncol. 1994; 1:5–10.

    Article  PubMed  CAS  Google Scholar 

  222. Stahl M, Wilke H, Fink U, et al. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. J Clin Oncol. 1996;14:829–837.

    PubMed  CAS  Google Scholar 

  223. Adelstein D, Rice T, Becker M, et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer. 1997;80:1011–1020.

    Article  PubMed  CAS  Google Scholar 

  224. Ganem G, Dubray B, Raoul Y, et al. Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus. J Clin Oncol. 1997;15:701–711.

    PubMed  CAS  Google Scholar 

  225. Wright C, Wain J, Lynch T, et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg. 1997;114:811–816.

    Article  PubMed  CAS  Google Scholar 

  226. Forastiere A, Heitmiller R, Kleinberg L, et al. Long follow-up of patients with esophageal cancer treated with preoperative cisplatin/5-FU and concurrent radiation. Proc Am Soc Clin Oncol. 1999;19:A1036.

    Google Scholar 

  227. Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy T. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–467.

    Article  PubMed  CAS  Google Scholar 

  228. LePrise E, Etienne P, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994;73:1779–1784.

    PubMed  Google Scholar 

  229. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepato-Gastroenterology. 1994;41:391–393.

    PubMed  CAS  Google Scholar 

  230. Urba S, Orringer M, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19: 305–313.

    PubMed  CAS  Google Scholar 

  231. Bleiberg H, Conroy T, Paillot B, et al. Randomized phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33:1216–1220.

    Article  PubMed  CAS  Google Scholar 

  232. Ajani J, Ilson D, Daugherty K, Pazdur R, Lynch P, Kelsen D. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994;86:1086–1091.

    PubMed  CAS  Google Scholar 

  233. Kelsen D, Ilson D, Wadleigh R, Leichmann L. A phase II multi-center trial of paclitaxel (P) [Taxol] as a weekly onehour infusion in advanced esophageal cancer (EC). Proc Am Soc Clin Oncol. 2000;19:A1266.

    Google Scholar 

  234. Slabber C, Falkson C, Musi N, Burger W. A phase II study of docetaxel in advanced, inoperable squamous carcinoma of the esophagus. Proc Am Soc Clin Oncol. 1999;18: A1511.

    Google Scholar 

  235. Enzinger P, Kulke M, Clark J, et al. Phase II trial of CPT-11 in previously untreated patietns with advanced adenocarcinoma of the esophagus and stomach. Proc Am Soc Clin Oncol. 2000;19:A1243.

    Google Scholar 

  236. Conroy T, Etienne P-L, Adenis A, et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol. 1996;14:164–170.

    PubMed  CAS  Google Scholar 

  237. Costa F, Ilson D, Forastiere A, et al. Phase II study of paclitaxel and cisplatin in patients with advanced adenocarcinoma (A) and squamous cell (S) carcinoma of the esophagus. Proc Am Soc Clin Oncol. 1997;16:A930.

    Google Scholar 

  238. Petrasch S, Welt A, Reinacher A, Graeven U, Konig M, Schmiegel W. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer. 1998;78:511–514.

    PubMed  CAS  Google Scholar 

  239. Ilson D, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999;17:3270–3275.

    PubMed  CAS  Google Scholar 

  240. Etienne P-L, Conroy T, Adenis A, et al. Vinorelbine and cisplatin in metastatic epidermoid carcinoma of the esophagus (MECE). An EORTC phase II study. Proc Am Soc Clin Oncol. 1999;18:A1037.

    Google Scholar 

  241. Kroep J, Peterss G, Giacone G, Pinedo H, vanGroeningen C. Phase II study of cisplatin (CDDP) preceding gemcitabine (GEM) in patients with advanced gastric and esophageal cancer. Proc Am Soc Clin Oncol. 2000;19: A1033.

    Google Scholar 

  242. Ou L, Chau G, Tsay S, et al. Clinicopathological comparison of resectable hepatocellular carcinoma between the young and the elderly patients. Chung Hua I Hsueh Tsa Chih (Taipei). 1997;60:40–47.

    CAS  Google Scholar 

  243. El-Serag H, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340: 745–750.

    Article  PubMed  CAS  Google Scholar 

  244. McQuillan G, Townsend T, Fields H, Carroll M, Leahy M, Polk B. Seroepidemiology of hepatitis B virus infection in the United States: 1976 to 1980. Am J Med. 1989;87:5S–10S.

    Article  PubMed  CAS  Google Scholar 

  245. McQuillan G, Alter M, Everhart J. Viral hepatitis. In: Everhart J, ed. Digestive Diseases in the United States: Epidemiology and Impact. NIH pub 94-1447. Washington, DC: Government Printing Office; 1994:127–156.

    Google Scholar 

  246. Peng Y, Chan C, Chen G. The effectiveness of serum alphafetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma. Hepatogastroenterology. 1999;46:3208–3211.

    PubMed  CAS  Google Scholar 

  247. McMahon B, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population study. Hepatology. 2000;32:842–846.

    Article  PubMed  CAS  Google Scholar 

  248. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174–181.

    PubMed  CAS  Google Scholar 

  249. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051–1055.

    Article  PubMed  CAS  Google Scholar 

  250. Nakakura E, Choti M. Management of hepatocellular carcinoma. Oncology. 2000;14:1085–1098.

    PubMed  CAS  Google Scholar 

  251. Carr B, Flickinger J, Lotze M. Hepatobiliatry cancers. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven; 1997:1087–1114.

    Google Scholar 

  252. Nagasue N, Uchida M, Makino Y, et al. Incidence and factors asociated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology. 1993;105:488–494.

    PubMed  CAS  Google Scholar 

  253. Chan E, Chow P, Tai B, Machin D, Soo K. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev. 2000;2: CD001199.

    PubMed  Google Scholar 

  254. Shiina S, Tagawa K, Niwa Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. Am J Roentgenol. 1993;160:1023–1028.

    CAS  Google Scholar 

  255. Lencioni R, Bartolozzi C, Caramella D, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients. Cancer. 1995;76:1737–1746.

    PubMed  CAS  Google Scholar 

  256. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology. 1995;197:101–108.

    PubMed  CAS  Google Scholar 

  257. Livraghi T, Lazzaroni S, Meloni F, Torzilli G, Vettori C. Intralesional ethanol in the treatment of unresectable liver cancer. World J Surg. 1995;19:801–806.

    Article  PubMed  CAS  Google Scholar 

  258. Group d’Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995;332:1256–1261.

    Article  Google Scholar 

  259. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol. 1998;29:129–134.

    Article  PubMed  CAS  Google Scholar 

  260. Poon R, Fan S, Lo C, et al. Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. Am J Gastroenterol. 1999;94:2460–2466.

    Article  PubMed  CAS  Google Scholar 

  261. Takenaka K, Shimada M, Higashi H, et al. Liver resection for hepatocellular carcinoma in the elderly. Arch Surg 1994;129:846–850.

    PubMed  CAS  Google Scholar 

  262. Hoshida Y, Ikeda K, Saito S, et al. The efficacy and prognosis of transcatheter chemoembolization for hepatocellular carcinoma in the elderly. Nippon Shokakibyo Gakkai Zasshi. 1999;96:142–146.

    PubMed  CAS  Google Scholar 

  263. Lui W, Chau G, Wu C. Surgical resection of hepatocellular carcinoma in elderly cirrhotic patients. Hepatogastroenterology. 1999;46:640–645.

    PubMed  CAS  Google Scholar 

  264. Pignata S, Izzo F, Farinati F, et al. Role of tamoxifen (TM) in the treatment of hepatocellular carcinoma (HCC). Results from the CLIP-01 randomized trial. Proc Am Soc Clin Oncol. 1998;17:A986.

    Google Scholar 

  265. Lowenfels A, Maisonneuve P, Boyle P, Zatonski W. Epidemiology of gallbladder cancer. Hepatogastroenterology. 1999;46:1529–1532.

    PubMed  CAS  Google Scholar 

  266. Pitt H, Dooley W, Yeo C, Cameron J. Malignancies of the biliary tree. Curr Probl Surg. 1995;32:1–90.

    PubMed  CAS  Google Scholar 

  267. Zatonski W, Lowenfels A, Boyle P, et al. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst. 1997;89:1132–1138.

    Article  PubMed  CAS  Google Scholar 

  268. DeGroen P, Gores G, LaRusso N, Gunderson L, Nagorney D. Biliary tract cancers. N Engl J Med. 1999;341:1368–1378.

    Article  PubMed  Google Scholar 

  269. Fong Y, Heffernan N, Blumgart L. Gallbladder carcinoma discovered during laparoscopic cholecystectomy: aggressive reresection is beneficial. Cancer. 1998;83:423–427.

    Article  PubMed  CAS  Google Scholar 

  270. Donohue J, Nagorney D, Grant C, Tsushima K, Ilstrup D, Adson M. Carcinoma of the gallbladder. Does radical resection improve outcome? Arch Surg. 1990;125:237–241.

    PubMed  CAS  Google Scholar 

  271. Bosset J, Mantion G, Gillet M, et al. Primary carcinoma of the gallbladder. Adjuvant postoperative external irradiation. Cancer. 1989;64:1843–1847.

    PubMed  CAS  Google Scholar 

  272. Mahe M, Stampfli C, Romestaing P, Salerno N, Gerard J. Primary carcinoma of the gall-bladder: potential for external radiation therapy. Radiother Oncol. 1994;33:204–208.

    Article  PubMed  CAS  Google Scholar 

  273. Foo M, Gunderson L, Bender C, Buskirk S. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys. 1997;39:929–935.

    Article  PubMed  CAS  Google Scholar 

  274. Bowling T, Galbraith S, Hatfield A, Solano J, Spittle M. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut. 1996;39:852–855.

    PubMed  CAS  Google Scholar 

  275. Kuvshinoff B, Armstrong J, Fong Y, et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg. 1995;82:1522–1525.

    PubMed  CAS  Google Scholar 

  276. Falkson G, MacIntyre J, Moertel C. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984;54:965–969.

    PubMed  CAS  Google Scholar 

  277. Lozano R, Patt Y, Hassan M, et al. Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer). Proc Am Soc Clin Oncol. 2000;19:A1025.

    Google Scholar 

Download references

Authors
  1. Peter C. Enzinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert J. Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Enzinger, P.C., Mayer, R.J. (2003). Colon Cancer and Other Gastrointestinal Malignancies. In: Geriatric Medicine. Springer, New York, NY. https://doi.org/10.1007/0-387-22621-4_35

Download citation

  • DOI: https://doi.org/10.1007/0-387-22621-4_35

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-95514-8

  • Online ISBN: 978-0-387-22621-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation